Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Adma Biologics (ADMA) over the last 11 years, with Q2 2025 value amounting to $143000.0.

  • Adma Biologics' Current Deferred Revenue fell 8734.51% to $143000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $143000.0, marking a year-over-year decrease of 8734.51%. This contributed to the annual value of $143000.0 for FY2024, which is 2142.86% down from last year.
  • Adma Biologics' Current Deferred Revenue amounted to $143000.0 in Q2 2025, which was down 8734.51% from $143000.0 recorded in Q1 2025.
  • Adma Biologics' 5-year Current Deferred Revenue high stood at $1.1 million for Q2 2024, and its period low was $142834.0 during Q1 2021.
  • Over the past 5 years, Adma Biologics' median Current Deferred Revenue value was $142834.0 (recorded in 2021), while the average stood at $254074.4.
  • In the last 5 years, Adma Biologics' Current Deferred Revenue soared by 69112.82% in 2024 and then plummeted by 8734.51% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Current Deferred Revenue stood at $142834.0 in 2021, then increased by 0.12% to $143000.0 in 2022, then rose by 27.27% to $182000.0 in 2023, then fell by 21.43% to $143000.0 in 2024, then changed by 0.0% to $143000.0 in 2025.
  • Its last three reported values are $143000.0 in Q2 2025, $143000.0 for Q1 2025, and $143000.0 during Q4 2024.